Does coexistence of endometrial cancer and adenomyosis affect survival outcomes? A retrospective cohort study

The aim of this study is to investigate cancer survival parameters in patients with a combination of adenomyosis and endometrial carcinoma in pathological specimens. This is a retrospective cohort study conducted in a tertiary health center. Between January 2010 and December 2016, a total of 370 patients with a diagnosis of endometrial carcinoma who had undergone at least total abdominal hysterectomy and bilateral salpingoopherectomy. After excluding the patients from the pathology after reviewing the reports, 76 patients with adenomyosis were included in the study group and 287 patients without adenomyosis were included in the control group. The mean age of all patients was 63.6 ± 8.2 years. The mortality rate was 9.2% in patients with adenomyosis and 12.9% in patients without adenomyosis (p = 0.382). Overall, the mean time from diagnosis to death was 41.8 ± 24.7 months, which did not differ between patients with adenomyosis (29.3 ± 18 months) and without adenomyosis (44.6 ± 25.4 months, (p = 0.117). The presence of adenomyosis did not significantly affect overall survival (p = 0.434) or disease-free survival (p = 0.146). Median disease-free survival was 119 months in patients without adenomyosis and 120 months in patients with adenomyosis. None of the factors we studied affected survival in patients with adenomyosis. In our study, the presence of adenomyosis was found in 20.9% of patients who underwent hysterectomy for endometrial cancer, and this association had neither a positive nor a negative impact on disease prognosis, i.e., mortality rate, disease-free survival and overall survival.

Adenomyosis; Endometrial carcinoma; Prognostic factor; Survive

[1] Houri O, Gil Y, Gemer O, Helpman L, Vaknin Z, Lavie O, et al. Prediction of endometrial cancer recurrence by using a novel machine learning algorithm: an Israeli gynecologic oncology group study. Journal of Gynecology Obstetrics and Human Reproduction. 2022; 51: 102466.

[2] Pecorino B, Laganà AS, Chiantera V, Ferrara M, Di Stefano AB, Di Donna MC, et al. Progression free survival, overall survival, and relapse rate in endometrioid ovarian cancer and synchronous endometrial-ovarian endometrioid cancer (SEO-EC): results from a large retrospective analysis. Medicina. 2022; 58: 1706.

[3] Lindfors A, Heshar H, Adok C, Sundfeldt K, Dahm-Kähler P. Long-term survival in obese patients after robotic or open surgery for endometrial cancer. Gynecologic Oncology. 2020; 158: 673–680.

[4] Matsuo K, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, et al. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. European Journal of Cancer. 2020; 133: 33–46.

[5] Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Human Reproduction Update. 2020; 26: 392–411.

[6] Hermens M, van Altena AM, Velthuis I, van de Laar DCM, Bulten J, van Vliet HAAM, et al. Endometrial cancer incidence in endometriosis and adenomyosis. Cancers. 2021; 13: 4592.

[7] Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Bordonne C, et al. Adenomyosis: an update regarding its diagnosis and clinical features. Journal of Gynecology Obstetrics and Human Reproduction. 2021; 50: 102228.

[8] Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. Journal of Obstetrics and Gynaecology Research. 2014; 40: 485–494.

[9] Hermens M, van Altena AM, van der Aa M, Bulten J, van Vliet HAAM, Siebers AG, et al. Endometrial cancer prognosis in women with endometriosis and adenomyosis: a retrospective nationwide cohort study of 40 840 women. International Journal of Cancer. 2022; 150: 1439–1446.

[10] Hanley KZ, Dustin SM, Stoler MH, Atkins KA. The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. International Journal of Gynecological Pathology. 2010; 29: 445–451.

[11] Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006; 20: 511–521.

[12] Rowlands IJ, Nagle CM, Spurdle AB, Webb PM. Gynecological conditions and the risk of endometrial cancer. Gynecologic Oncology. 2011; 123: 537–541.

[13] An M, Duan H, Zhang Y. Prognostic significance of co-existent adenomyosis on outcomes and tumor characteristics of endometrial cancer: a meta-analysis. Journal of Obstetrics and Gynaecology Research. 2020; 46: 1851–1863.

[14] Szubert M, Kozirog E, Wilczynski J. Adenomyosis as a risk factor for myometrial or endometrial neoplasms-review. International Journal of Environmental Research and Public Health. 2022; 19: 2294.

[15] Yilmaz A, Cokmez H, Gulbahar A. Effect of coexisting adenomyosis on patients with endometrioid adenocarcinoma: Determination of intraoperative risk factors for tumor metastasis and estimation of prognosis. Journal of Cancer Research and Therapeutics. 2022; 18: 599–602.

[16] da Silva JR, Andres MP, Leite APK, Gomes MTNA, Neto JS, Baracat EC, et al. Comparison of sensitivity and specificity of structured and narrative reports of transvaginal ultrasonogaphy for adenomyosis. Journal of Minimally Invasive Gynecology. 2021; 28: 1216–1224.

[17] Palena C, Hamilton DH, Fernando RI. Infuence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncology. 2012; 8: 713–722.

[18] Aslan K, Sarı ME, Yalçın HR, Yalçın İ, Cüylan ZF, Özdal B. Coexistence of uterine adenomyosis is not associated with a better prognosis in endometrioid-type endometrial cancer. Irish Journal of Medical Science. 2020; 189: 835–842.

[19] İşgüder ÇK, Doğru HY, Özsoy AZ, Çakmak B, Delibaş İB, Arici A, et al. The Evaluation of Histopathological Diagnosis in Hysterectomy Materials. Journal of Contemporary Medicine. 2016; 6: 87–91.

[20] Upson K, Missmer SA. Epidemiology of adenomyosis. Seminars in Reproductive Medicine. 2020; 38: 89–107.

[21] Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Human Reproduction Update. 2021; 27: 1086–1097.

[22] Khan KN, Fujishita A, Mori T. Pathogenesis of human adenomyosis: current understanding and its association with infertility. Journal of Clinical Medicine. 2022; 11: 4057.

[23] Li X, Pan N, Zhang W, Wang Y, Ge Y, Wei H, et al. Association between uterine volume and pregnancy outcomes in adenomyosis patients undergoing frozen-thawed embryo transfer. Reproductive BioMedicine Online. 2021; 42: 384–389.

[24] Hu H, Li H, He Y. MicroRNA-17 downreguates expression of the PTEN gene to promote the occurrence and development of adenomyosis. Experimental and Therapeutic Medicine. 2017; 14: 3805–3811.

[25] Machida H, Maeda M, Cahoon SS, Scannell CA, Garcia-Sayre J, Roman LD, et al. Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two diferent entities? Archives of Gynecology and Obstetrics. 2017; 295: 1459–1468.

[26] Johnatty SE, Stewart CJR, Smith D, Nguyen A, O' Dwyer J, O’Mara TA, et al. Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer. Scientific Reports. 2020; 10: 3621.

[27] Yun JB, Jong-Min L, Seung YP. Endometrial adenocarcinoma arising in adenomyosis: case report and review of literature. European Journal of Gynaecological Oncology. 2020; 41: 858–862.

[28] Taneichi A, Fujiwara H, Takahashi Y, Takei Y, Machida S, Saga Y, et al. Influences of uterine adenomyosis on muscle invasion and prognosis of endometrioid adenocarcinoma. International Journal of Gynecologic Cancer. 2014; 24: 1429–1433.

[29] Raffone A, Travaglino A, Raimondo D, Maletta M, Salucci P, Santoro A, et al. Histological prognostic factors of endometrial cancer in patients with adenomyosis: a systematic review and meta-analysis. Pathobiology. 2022; 89: 127–134.

[30] Murphy AR, Campo H, Kim JJ. Strategies for modelling endometrial diseases. Nature Reviews Endocrinology. 2022; 18: 727–743.

[31] Musa F, Frey MK, Im HB, Chekmareva M, Ellenson LH, Holcomb K. Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium? American Journal of Obstetrics and Gynecology. 2012; 207: 417.e1–417.e6.

[32] Matsuo K, Cahoon SS, Gualtieri M, Scannell CA, Jung CE, Takano T, et al. Signifcance of adenomyosis on tumor progression and survival outcome of endometrial cancer. Annals of Surgical Oncology. 2014; 21: 4246–4255.

[33] Koshiyama M, Okamoto T, Ueta M. The relationship between endometrial carcinoma and coexistent adenomyosis uteri, endometriosis externa and myoma uteri. Cancer Detection and Prevention. 2004; 28: 94–98.

[34] Mao X, Zheng W, Mao W. Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: a case series. Medicine. 2017; 96: e8336.

[35] Boonlak S, Aue-Aungkul A, Kietpeerakool C, Kleebkaow P, Chumworathayi B, Luanratanakorn S, et al. Impact of coexisting uterine adenomyosis on the survival outcome of patients with endometrial cancer: a retrospective cohort study. Asian Pacific Journal of Cancer Prevention. 2019; 20: 1185–1190.

[36] Zouzoulas OD, Tsolakidis D, Efstratiou I, Pervana S, Pazarli E, Grimbizis G. Correlation between adenomyosis and endometrial cancer: 6-year experience of a single center. Facts, Views & Vision in ObGyn. 2018; 10: 147–152.